Direxion Daily Semicondct Bull 3X ETF

Bank Of Montreal

Direxion Daily Technology Bull 3X ETF

GraniteShares 1.5x Long Coinbase Daily ETF

ProShares UltraPro QQQ

AXS 2X Innovation ETF

ProShares UltraPro S&P500

Direxion Daily S&P500 Bull 3X ETF

Direxion Daily Small Cap Bull 3X ETF

Direxion Daily Semicondct Bear 3X ETF

Direxion Technology Bear 3X Shares

ProShares UltraPro Short QQQ

VS TR 2x Long VIX Futures ETF

MicroSectors Gold Miners -3X Inverse Leveraged ETNs

Direxion Daily S&P 500 Bear 3X ETF

ProShares Ultra VIX Short-Term Futures

Direxion Daily Small Cap Bear 3X ETF

KWESST Micro Systems Inc. Common Stock

Odyssey Marine Exploration Inc. Common Stock

Upexi Inc. Common Stock

ServiceNow Inc. Common Stock

Comfort Systems USA Inc. Common Stock

Microchip Technology Incorporated Common Stock

Nano Nuclear Energy Inc. Common Stock

Alpha and Omega Semiconductor Limited Common Shares

Applied Optoelectronics Inc. Common Stock

AgEagle Aerial Systems Inc. Common Stock

ASGN Incorporated Common Stock

Alaska Air Group Inc. Common Stock

International Business Machines Corporation Common Stock

Novavax Inc. Common Stock

Century Communities Inc. Common Stock

Molina Healthcare Inc Common Stock

Beyond Meat Inc. Common Stock

PepsiCo Inc. Common Stock

T-Mobile US Inc. Common Stock

Macy's Inc Common Stock

Click here to get full coverage on Trading (DTIL) With Integrated Risk Controls - news.stocktradersdaily.com

Trading (DTIL) With Integrated Risk Controls  news.stocktradersdaily.com

Trading (DTIL) With Integrated Risk Controls - news.stocktradersdaily.com

Click here to get full coverage on $DTIL stock is up 13% today. Here's what we see in our data. - Nasdaq

$DTIL stock is up 13% today. Here's what we see in our data.  Nasdaq

$DTIL stock is up 13% today. Here's what we see in our data. - Nasdaq

Click here to get full coverage on Breakthrough: Precision BioSciences' Gene Editing Therapy Delivers First Results in HBV Patients - Stock Titan

Breakthrough: Precision BioSciences' Gene Editing Therapy Delivers First Results in HBV Patients  Stock Titan

Breakthrough: Precision BioSciences' Gene Editing Therapy Delivers First Results in HBV Patients - Stock Titan

Click here to get full coverage on Precision BioSciences (DTIL) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance

Precision BioSciences (DTIL) Reports Q4 Loss, Misses Revenue Estimates  Yahoo Finance

Precision BioSciences (DTIL) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance

Click here to get full coverage on DTIL Gets FDA's Fast Track Tag for Hepatitis B Gene Therapy, Stock Up - Zacks Investment Research

DTIL Gets FDA's Fast Track Tag for Hepatitis B Gene Therapy, Stock Up  Zacks Investment Research

DTIL Gets FDA's Fast Track Tag for Hepatitis B Gene Therapy, Stock Up - Zacks Investment Research

Click here to get full coverage on Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025 - Business Wire

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025  Business Wire

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025 - Business Wire

Click here to get full coverage on Precision Bio gains on early Phase 1 data for Hep B candidate - Seeking Alpha

Precision Bio gains on early Phase 1 data for Hep B candidate  Seeking Alpha

Precision Bio gains on early Phase 1 data for Hep B candidate - Seeking Alpha

Click here to get full coverage on Precision BioSciences Earnings Call: Key ARCUS Gene Editing Platform Updates Expected March 26 - Stock Titan

Precision BioSciences Earnings Call: Key ARCUS Gene Editing Platform Updates Expected March 26  Stock Titan

Precision BioSciences Earnings Call: Key ARCUS Gene Editing Platform Updates Expected March 26 - Stock Titan

Click here to get full coverage on PRECISION BIOSCIENCES Earnings Preview: Recent $DTIL Insider Trading, Hedge Fund Activity, and More - Nasdaq

PRECISION BIOSCIENCES Earnings Preview: Recent $DTIL Insider Trading, Hedge Fund Activity, and More  Nasdaq

PRECISION BIOSCIENCES Earnings Preview: Recent $DTIL Insider Trading, Hedge Fund Activity, and More - Nasdaq

Click here to get full coverage on Precision Bio stock upgraded at BMO (update) (DTIL:NASDAQ) - Seeking Alpha

Precision Bio stock upgraded at BMO (update) (DTIL:NASDAQ)  Seeking Alpha

Precision Bio stock upgraded at BMO (update) (DTIL:NASDAQ) - Seeking Alpha

Click here to get full coverage on Precision BioSciences Announces Oral Presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference - Business Wire

Precision BioSciences Announces Oral Presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference  Business Wire

Precision BioSciences Announces Oral Presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference - Business Wire

Click here to get full coverage on Gene Editing Pioneer Reshapes C-Suite: Inside Precision BioSciences' Strategic Leadership Evolution - Stock Titan

Gene Editing Pioneer Reshapes C-Suite: Inside Precision BioSciences' Strategic Leadership Evolution  Stock Titan

Gene Editing Pioneer Reshapes C-Suite: Inside Precision BioSciences' Strategic Leadership Evolution - Stock Titan

Click here to get full coverage on Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference - Business Wire

Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference  Business Wire

Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference - Business Wire

Click here to get full coverage on Revolutionary DMD Treatment Restores 93% Muscle Strength, Could Help 60% of Patients - Stock Titan

Revolutionary DMD Treatment Restores 93% Muscle Strength, Could Help 60% of Patients  Stock Titan

Revolutionary DMD Treatment Restores 93% Muscle Strength, Could Help 60% of Patients - Stock Titan

Click here to get full coverage on Revolutionary Gene Editing Treatment for Hepatitis B Wins FDA Fast Track Status - Stock Titan

Revolutionary Gene Editing Treatment for Hepatitis B Wins FDA Fast Track Status  Stock Titan

Revolutionary Gene Editing Treatment for Hepatitis B Wins FDA Fast Track Status - Stock Titan

Click here to get full coverage on Revolutionary Gene Therapy Achieves 99% Hepatitis B Virus Elimination - Key Trial Updates - Stock Titan

Revolutionary Gene Therapy Achieves 99% Hepatitis B Virus Elimination - Key Trial Updates  Stock Titan

Revolutionary Gene Therapy Achieves 99% Hepatitis B Virus Elimination - Key Trial Updates - Stock Titan

Click here to get full coverage on Revolutionary Gene Editing Breakthrough: FDA Greenlights First-Ever Hepatitis B Cure Attempt - Stock Titan

Revolutionary Gene Editing Breakthrough: FDA Greenlights First-Ever Hepatitis B Cure Attempt  Stock Titan

Revolutionary Gene Editing Breakthrough: FDA Greenlights First-Ever Hepatitis B Cure Attempt - Stock Titan

Click here to get full coverage on (DTIL) Trading Advice - news.stocktradersdaily.com

(DTIL) Trading Advice  news.stocktradersdaily.com

(DTIL) Trading Advice - news.stocktradersdaily.com

Click here to get full coverage on FDA Fast Tracks Precision BioSciences' (DTIL) Hepatitis B Gene Editing Program | DTIL Stock News - GuruFocus

FDA Fast Tracks Precision BioSciences' (DTIL) Hepatitis B Gene Editing Program | DTIL Stock News  GuruFocus

FDA Fast Tracks Precision BioSciences' (DTIL) Hepatitis B Gene Editing Program | DTIL Stock News - GuruFocus

Click here to get full coverage on Precision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency - Business Wire

Precision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency  Business Wire

Precision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency - Business Wire

Click here to get full coverage on Precision BioSciences to Report Q3 Earnings: What's in the Cards? - Yahoo Finance

Precision BioSciences to Report Q3 Earnings: What's in the Cards?  Yahoo Finance

Precision BioSciences to Report Q3 Earnings: What's in the Cards? - Yahoo Finance

Click here to get full coverage on Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update - Business Wire

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update  Business Wire

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update - Business Wire

Click here to get full coverage on Precision BioSciences Strengthens Senior Leadership Team to Drive Multiple In Vivo Gene Editing Programs - Business Wire

Precision BioSciences Strengthens Senior Leadership Team to Drive Multiple In Vivo Gene Editing Programs  Business Wire

Precision BioSciences Strengthens Senior Leadership Team to Drive Multiple In Vivo Gene Editing Programs - Business Wire

Click here to get full coverage on Breakthrough: First Infant Successfully Treated in iECURE's OTC Deficiency Gene Therapy Trial - Stock Titan

Breakthrough: First Infant Successfully Treated in iECURE's OTC Deficiency Gene Therapy Trial  Stock Titan

Breakthrough: First Infant Successfully Treated in iECURE's OTC Deficiency Gene Therapy Trial - Stock Titan

Click here to get full coverage on Precision BioSciences to Participate in Upcoming November Investor Conferences - Business Wire

Precision BioSciences to Participate in Upcoming November Investor Conferences  Business Wire

Precision BioSciences to Participate in Upcoming November Investor Conferences - Business Wire

Click here to get full coverage on Precision & TG Therapeutics: Unlocking Value With ARCUS, BRIUMVI And Azer-Cel (NASDAQ:DTIL) - Seeking Alpha

Precision & TG Therapeutics: Unlocking Value With ARCUS, BRIUMVI And Azer-Cel (NASDAQ:DTIL)  Seeking Alpha

Precision & TG Therapeutics: Unlocking Value With ARCUS, BRIUMVI And Azer-Cel (NASDAQ:DTIL) - Seeking Alpha

Click here to get full coverage on Precision BioSciences upgraded to Outperform at BMO on favorable risk/reward - Investing.com

Precision BioSciences upgraded to Outperform at BMO on favorable risk/reward  Investing.com

Precision BioSciences upgraded to Outperform at BMO on favorable risk/reward - Investing.com

Click here to get full coverage on Precision BioSciences shares soar on promising gene editing trial results - Investing.com

Precision BioSciences shares soar on promising gene editing trial results  Investing.com

Precision BioSciences shares soar on promising gene editing trial results - Investing.com

Click here to get full coverage on Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B | DTIL Stock News - GuruFocus

Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B | DTIL Stock News  GuruFocus

Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B | DTIL Stock News - GuruFocus

Click here to get full coverage on Precision BioSciences: Q4 Earnings Snapshot - Huron Daily Tribune

Precision BioSciences: Q4 Earnings Snapshot  Huron Daily Tribune

Precision BioSciences: Q4 Earnings Snapshot - Huron Daily Tribune

Click here to get full coverage on Long Term Trading Analysis for (DTIL) - news.stocktradersdaily.com

Long Term Trading Analysis for (DTIL)  news.stocktradersdaily.com

Long Term Trading Analysis for (DTIL) - news.stocktradersdaily.com

Click here to get full coverage on Precision BioSciences stock hits 52-week low at $4.12 - Investing.com

Precision BioSciences stock hits 52-week low at $4.12  Investing.com

Precision BioSciences stock hits 52-week low at $4.12 - Investing.com

Click here to get full coverage on 12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session  Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga

Click here to get full coverage on Precision BioSciences Receives $13 Million in Proceeds from Imugene Convertible Note Maturity as Part of the August 2023 Azer-cel Deal - Business Wire

Precision BioSciences Receives $13 Million in Proceeds from Imugene Convertible Note Maturity as Part of the August 2023 Azer-cel Deal  Business Wire

Precision BioSciences Receives $13 Million in Proceeds from Imugene Convertible Note Maturity as Part of the August 2023 Azer-cel Deal - Business Wire

Click here to get full coverage on Precision BioSciences announces board member's retirement - Investing.com

Precision BioSciences announces board member's retirement  Investing.com

Precision BioSciences announces board member's retirement - Investing.com

Click here to get full coverage on BCRX: 3 High-Potential Biotech Stocks Under $10 - StockNews

BCRX: 3 High-Potential Biotech Stocks Under $10  StockNews

BCRX: 3 High-Potential Biotech Stocks Under $10 - StockNews

Click here to get full coverage on Precision BioSciences (DTIL) Stock Forecast and Price Target 2025 - MarketBeat

Precision BioSciences (DTIL) Stock Forecast and Price Target 2025  MarketBeat

Precision BioSciences (DTIL) Stock Forecast and Price Target 2025 - MarketBeat

Click here to get full coverage on Precision Biosciences CEO sells $5,359 in stock By Investing.com - Investing.com UK

Precision Biosciences CEO sells $5,359 in stock By Investing.com  Investing.com UK

Precision Biosciences CEO sells $5,359 in stock By Investing.com - Investing.com UK

Click here to get full coverage on Why Precision BioSciences Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket - Benzinga

Why Precision BioSciences Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket  Benzinga

Why Precision BioSciences Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket - Benzinga

Click here to get full coverage on Precision BioSciences Reports Positive 2024 Financial Results - TipRanks

Precision BioSciences Reports Positive 2024 Financial Results  TipRanks

Precision BioSciences Reports Positive 2024 Financial Results - TipRanks

Click here to get full coverage on FDA fast tracks Precision BioSciences’ hepatitis B treatment - Investing.com Australia

FDA fast tracks Precision BioSciences’ hepatitis B treatment  Investing.com Australia

FDA fast tracks Precision BioSciences’ hepatitis B treatment - Investing.com Australia

Click here to get full coverage on H.C. Wainwright maintains $60 target on Precision BioSciences stock By Investing.com - Investing.com UK

H.C. Wainwright maintains $60 target on Precision BioSciences stock By Investing.com  Investing.com UK

H.C. Wainwright maintains $60 target on Precision BioSciences stock By Investing.com - Investing.com UK

Click here to get full coverage on Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement - Business Wire

Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement  Business Wire

Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement - Business Wire

Click here to get full coverage on Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants - Business Wire

Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants  Business Wire

Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants - Business Wire

Click here to get full coverage on After Plunging -27.45% in 4 Weeks, Here's Why the Trend Might Reverse for Precision BioSciences (DTIL) - Yahoo Finance

After Plunging -27.45% in 4 Weeks, Here's Why the Trend Might Reverse for Precision BioSciences (DTIL)  Yahoo Finance

After Plunging -27.45% in 4 Weeks, Here's Why the Trend Might Reverse for Precision BioSciences (DTIL) - Yahoo Finance

Click here to get full coverage on HC Wainwright & Co. Reiterates Precision Biosciences (DTIL) Buy Recommendation - Nasdaq

HC Wainwright & Co. Reiterates Precision Biosciences (DTIL) Buy Recommendation  Nasdaq

HC Wainwright & Co. Reiterates Precision Biosciences (DTIL) Buy Recommendation - Nasdaq

Click here to get full coverage on DTIL Stock Price and Chart — NASDAQ:DTIL - TradingView

DTIL Stock Price and Chart — NASDAQ:DTIL  TradingView

DTIL Stock Price and Chart — NASDAQ:DTIL - TradingView

Click here to get full coverage on Precision BioSciences Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Precision BioSciences Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)  Business Wire

Precision BioSciences Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Click here to get full coverage on MDEC zeroes in on Malaysia tourism scene through the Digital Tourism Innovation Lab - webintravel.com

MDEC zeroes in on Malaysia tourism scene through the Digital Tourism Innovation Lab  webintravel.com

MDEC zeroes in on Malaysia tourism scene through the Digital Tourism Innovation Lab - webintravel.com

Click here to get full coverage on Precision BioSciences: Uniquely Positioned (NASDAQ:DTIL) - Seeking Alpha

Precision BioSciences: Uniquely Positioned (NASDAQ:DTIL)  Seeking Alpha

Precision BioSciences: Uniquely Positioned (NASDAQ:DTIL) - Seeking Alpha

Click here to get full coverage on Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics - Business Wire

Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics  Business Wire

Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics - Business Wire

Click here to get full coverage on Precision BioSciences (DTIL) Stock Price, News & Analysis - MarketBeat

Precision BioSciences (DTIL) Stock Price, News & Analysis  MarketBeat

Precision BioSciences (DTIL) Stock Price, News & Analysis - MarketBeat

Click here to get full coverage on Precision BioSciences Appoints Michael Amoroso Chief Executive Officer - Business Wire

Precision BioSciences Appoints Michael Amoroso Chief Executive Officer  Business Wire

Precision BioSciences Appoints Michael Amoroso Chief Executive Officer - Business Wire

Click here to get full coverage on Precision BioSciences Launches IPO to Raise $126.4 Million - BioSpace

Precision BioSciences Launches IPO to Raise $126.4 Million  BioSpace

Precision BioSciences Launches IPO to Raise $126.4 Million - BioSpace

Click here to get full coverage on Precision BioSciences Appoints Alex Kelly as Chief Financial Officer - BioSpace

Precision BioSciences Appoints Alex Kelly as Chief Financial Officer  BioSpace

DTIL

Price Chart

Key Statistics

Technicals

About DTIL

Latest News

Trading (DTIL) With Integrated Risk Controls - news.stocktradersdaily.com

$DTIL stock is up 13% today. Here's what we see in our data. - Nasdaq

Breakthrough: Precision BioSciences' Gene Editing Therapy Delivers First Results in HBV Patients - Stock Titan

Advanced Charts

Top Gainers

Top Losers